NCT01187199 2026-04-16
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
246 trialsNCT01642017 2026-04-14
VOTRAGE
Institut Claudius Regaud
Phase 1 Terminated
NCT04520711 2026-04-13
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Providence Health & Services
Phase 1 Active not recruiting
NCT07144085 2026-04-03
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
First Hospital of China Medical University
Phase 1 Recruiting
NCT02133625 2026-03-30
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT05887882 2026-03-30
PNOC028
University of California, San Francisco
Phase 1 Recruiting
NCT03568058 2026-03-24
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
Phase 1 Completed
NCT06911008 2026-03-19
MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
Mayo Clinic
Phase 1 Recruiting
NCT06298357 2026-03-18
Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation
University of Alabama at Birmingham
Phase 1 Completed
NCT05694715 2026-03-17
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
Phase 1 Recruiting
NCT01374620 2026-03-16
PAL-ANGI2
Centre Oscar Lambret
Phase 1 Completed
NCT07474168 2026-03-16
T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Zhejiang University
Phase 1 Active not recruiting
NCT04693468 2026-03-13
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07454031 2026-03-13
Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma
Peking University
Phase 1 Not yet recruiting
NCT07197671 2026-03-12
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
University of Wisconsin, Madison
Phase 1 Recruiting
NCT05707910 2026-03-09
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
West China Hospital
Phase 1 Active not recruiting
NCT07269080 2026-03-02
STM-06
University of Illinois at Chicago
Phase 1 Recruiting
NCT06389123 2026-02-27
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
University of California, Davis
Phase 1 Recruiting
NCT03203525 2026-02-25
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06524570 2026-02-18
iFOCUS
UMC Utrecht
Phase 1 Recruiting
NCT07404332 2026-02-11
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Phase 1 Not yet recruiting
NCT07348042 2026-01-16
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors
Fudan University
Phase 1 Recruiting
NCT07348107 2026-01-16
ATARI-PDAC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1 Not yet recruiting
NCT03065387 2026-01-12
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02560636 2026-01-06
PLUMMB
Royal Marsden NHS Foundation Trust
Phase 1 Active not recruiting
NCT06337630 2026-01-02
POP-ART
Institut Curie
Phase 1 Terminated
NCT04621435 2025-12-31
Imaging of Solid Tumors Using FAP-2286
University of California, San Francisco
Phase 1 Recruiting
NCT06043713 2025-12-19
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT05338658 2025-12-09
Study of PAT in Patients With Solid Tumor Cancers
Masonic Cancer Center, University of Minnesota
Phase 1 Recruiting
NCT07269899 2025-12-08
Reboot-107
Sun Yat-sen University
Phase 1 Recruiting
NCT06478251 2025-11-25
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Zhejiang University
Phase 1 Recruiting
NCT06484790 2025-11-25
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Recruiting
NCT05631899 2025-11-24
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1 Active not recruiting
NCT02321501 2025-11-10
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05195710 2025-11-10
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06644170 2025-10-14
A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer
University of Washington
Phase 1 Completed
NCT04295863 2025-10-01
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
University of Chicago
Phase 1 Recruiting
NCT04361708 2025-10-01
I-FLOAT
University of Chicago
Phase 1 Recruiting
NCT06296056 2025-10-01
SDH-Combi
Seoul Hospital
Phase 1 Completed
NCT01061515 2025-09-17
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT06549478 2025-09-17
Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
City of Hope Medical Center
Phase 1 Recruiting
NCT05204147 2025-09-16
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
City of Hope Medical Center
Phase 1 Recruiting
NCT03036228 2025-09-09
MASTIFF
Thomas Helleday Foundation
Phase 1 Completed
NCT07086768 2025-09-04
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Not yet recruiting
NCT03611595 2025-08-28
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
University of California, San Diego
Phase 1 Recruiting
NCT07121036 2025-08-13
High - Dose Vitamin C Infusion Regimen Based on Pharmacokinetic Characteristics for Patients With Advanced Malignant Solid Tumors
Zhongnan Hospital
Phase 1 Recruiting
NCT06484556 2025-07-31
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Recruiting
NCT02775292 2025-07-30
NYM
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT06416436 2025-06-29
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
University of Kansas Medical Center
Phase 1 Withdrawn